Charles River Laboratories (CRL) Tops Q1 EPS by 8c; Boosts FY16 EPS Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts CRL Hot Sheet
Price: $326.29 -7.27%
Financial Fact:
Provision (benefit) for income taxes: 15.57M
Today's EPS Names:
ARIS, COHR, ATS, More
Financial Fact:
Provision (benefit) for income taxes: 15.57M
Today's EPS Names:
ARIS, COHR, ATS, More
Join SI Premium – FREE
Charles River Laboratories (NYSE: CRL) reported Q1 EPS of $0.98, $0.08 better than the analyst estimate of $0.90. Revenue for the quarter came in at $354.9 million versus the consensus estimate of $354.91 million.
GUIDANCE:
Charles River Laboratories sees FY2016 EPS of $4.32-$4.45, versus the consensus of $4.34.
For earnings history and earnings-related data on Charles River Laboratories (CRL) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Veracyte (VCYT) Tops Q3 EPS by 10c ; Offers Guidance
- Myriad Genetics (MYGN) Tops Q3 EPS by 9c ; Offers Guidance
- Sezzle Inc. (SEZL) Reports Q3 EPS of $1.37 ; Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
